FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
April 17, 2026
Foley Viewpoints
Texas Attorney General Investigates Lululemon Over Alleged “Forever Chemicals” in Activewear. What This Signals for Consumer Products, Apparel, and Wellness Brands
Summary The Texas Attorney General (AG) has issued a Civil Investigative Demand to Lululemon USA Inc. (Lululemon) to examine whether the…
April 15, 2026
Foley Viewpoints
Those Unpredictable Teen Years: A Practical Guide to Considerations for Maturing ESOPs
Employee stock ownership plans (ESOPs) have proven to be powerful tools for aligning employee interests with company success and creating…
April 15, 2026
Foley Viewpoints
Demystifying the Duty of Prudence: DOL Proposes ERISA Safe Harbor for Designated Investment Alternatives in Retirement Plans
On March 31, 2026, the Department of Labor (DOL) published a proposed regulation (the Proposed Regulation) creating a new safe harbor for…